Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor

US11459390B2 · kind B2 · utility

Assignees

• Novartis AG · CH
• The Trustees of the University of Pennsylvania · US

Inventors

• Jennifer Brogdon · Cambridge, US
• Hilmar Erhard Ebersbach · Basel, CH
• David Glass · Cambridge, US
• Thomas Huber · Basel, CH
• Julia Jascur · Basel, CH
• Carl H. June · Yeadon, US
• Jihyun Lee · Wynnebrook Manor, US
• Joan Mannick · Cambridge, US
• Michael C. Milone · Cherry Hill, US
• Leon Murphy · Cambridge, US
• Avery D. Posey · Philadelphia, US
• Huijuan Song · Shanghai, CN
• Yongqiang Wang · Shanghai, CN
• Lai Wei · Kowloon, CN
• Qilong Wu · Shanghai, CN
• Qiumei Yang · Shanghai, CN
• Jiquan Zhang · Shanghai, CN

Key dates

• Filing date: Jan 15, 2016
• Grant date: Oct 4, 2022
• Expiry date: Mar 5, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2800/60
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.